# ACT-1: HCP commentary report > 5 verified statements (2 from clinicians verified by NPI or staff page) from 2 commentary sources · 3 findings · updated Oct 31, 2026 ## Report - Trial: A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas - NCT ID: NCT00646854 - Registry: https://clinicaltrials.gov/study/NCT00646854 - Sponsor: Aarhus University Hospital - Phase: Phase 3 - Status: Completed - Drugs tested: alemtuzumab - Indication: previously untreated peripheral T-cell lymphoma - Version: v1.0.0, edition 1 - Accepted: 2026-10-31 - Last checked: 2026-10-31 - Release hash: bfb46da31bc8ef0e68297741f34d78631f8150cb8a9557ad711b8bcfd525fde1 ## Counts - HCP commentary sources screened: 33 - Sources cited by verified statements: 2 - Verified statements: 5 - From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 2 - Findings: 3 - Named people in screened sources (unnamed speakers and accounts not counted): 2 - Voices cited: 2 - Cited voices identity-verified: 2 - Organisational or shared accounts (not counted as people): 1 Counts describe the retained sources. They do not estimate how many HCPs hold a view. ## Abstract ACT-1 asks whether adding alemtuzumab to two-weekly CHOP improves event-free survival in younger patients with untreated systemic peripheral T-cell lymphoma receiving autologous transplant consolidation. Commentary comes from X posts. The discussion turns on whether alemtuzumab adds survival benefit to CHOP, with one speaker offering a negative interpretation across studies. Further questions concern CD52 assessment methods and how to interpret interest in response rates with broader CHOP combinations. ## Open Medical Affairs question How should response-rate interest be framed alongside a nonspecific survival conclusion and CD52-assessment concerns? Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question. ## Findings (titles) - F1. The no-survival-benefit interpretation spans several studies - F2. CD52 assessment draws a methodological criticism - F3. Broader X+CHOP interest includes a relayed high-response-rate assessment ## What sits behind each finding Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. | Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations | | --- | ---: | ---: | ---: | ---: | --- | ---: | | F1 | 2 | 1 | 1 | 1 | none recorded | 1 | | F2 | 1 | 1 | 1 | 1 | none recorded | 1 | | F3 | 2 | 1 | 1 | 1 | none recorded | 2 | ### What the statements are | Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question | | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- | | F1 | 1 | 0 | 0 | 1 | 0 | 2 | 0 | 1 post or article | yes | | F2 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 post or article | yes | | F3 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 1 post or article | yes | ### Trial dimensions - Primary endpoint: Event-free Survival: no finding draws on it directly - Secondary endpoints: F3 (1 shared claims) - Population and setting: no finding draws on it directly - The comparison: F1 (2 shared claims) - Safety and tolerability: no finding draws on it directly - Design and conduct: no finding draws on it directly ## Sample findings Paraphrased; the full report links each statement to its source. ### F1. The no-survival-benefit interpretation spans several studies An X post prompts a methodological question: how should a survival interpretation spanning alemtuzumab–CHOP studies be distinguished from conclusions about ACT-1-specific endpoints? Short quotations should be accompanied by a link to the original post. Source: X thread, 2019-03-02. ## What's inside | Section | Items | Access | | --- | ---: | --- | | Findings with interpretation, counterviews and limits | 3 | Titles free | | Detailed analysis | 4 sections | Paid | | Verified statements with short source quotes and links | 5 | Paid | | Trial aspects mapped | 8 | Free | | Sources with links | 2 | Counts free | | Speaker attribution for cited voices | 2 | Paid | ## Trial aspects 4 discussed · 4 no commentary found · 0 assessment incomplete. | Aspect | Coverage | Statements | Sources | | --- | --- | ---: | ---: | | Primary endpoint: Event-free Survival | no commentary found | 0 | 0 | | Secondary endpoints | discussed | 1 | 1 | | Population and setting | no commentary found | 0 | 0 | | The comparison | discussed | 2 | 1 | | Safety and tolerability | no commentary found | 0 | 0 | | Design and conduct | no commentary found | 0 | 0 | | CD52 assessment: immunohistochemistry versus flow analysis | discussed | 1 | 1 | | Broader X+CHOP interest and relayed response rates | discussed | 2 | 1 | An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it. ## Sources | Channel | Screened | Cited | | --- | ---: | ---: | | X threads | 14 | 2 | | Bluesky threads | 14 | 0 | | Podcasts | 3 | 0 | | YouTube | 2 | 0 | - Screened window: 2019-03-02 to 2026-10-25 - Cited window: 2019-03-02 to 2023-06-14 - Retrieved: 2026-10-31 Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context. ## The trial From ClinicalTrials.gov. - Title: A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas - Registry: NCT00646854 (https://clinicaltrials.gov/study/NCT00646854) - Study IDs: 2006-006130-17 - Sponsor: Aarhus University Hospital - Collaborators: GCP-unit at Aarhus University Hospital, Aarhus, Denmark - Design: Phase 3 · interventional, randomized, parallel, phase3 - Status: Completed - Enrollment: 136 (actual) - Start: 2008-06 (actual) - Primary completion: 2016-12-31 (actual) - Primary endpoint: Event-free Survival (The EFS is defined by the time between day of randomization until an event occurs, up to 96 months) - Intervention: CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab (drug) - Intervention: CHOP14 chemotherapy (see specification under Arm B) plus G-CSF (drug) ## Scope and limits This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice. - Discussion that does not name the trial may be missing from this edition. - Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition. - 2 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted. - Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included. - The findings rest on two short X posts. Relevant discussion that does not name the trial may be missing, and two passages were not fully assessed for clinician views. - No results publication for NCT00646854 or trial protocol was available among the sources reviewed for this edition; the posts cannot substitute for a trial-specific quantitative assessment. - The survival statement lacks an identified endpoint, time point and estimate; the relayed response-rate statement lacks an identified study, numerical rate, definition and time point. - These statements do not establish treatment recommendations, safety reassurance, stem-cell-harvest feasibility or agreement across HCPs. How reports are built and checked: https://www.erudio.com/methods ## Editions and corrections - v1.0.0, accepted 2026-10-31: current edition Last checked for new commentary 2026-10-31. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch. ## Offer - Size: Focused (5 verified statements) - Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge - 3 months of weekly updates: $1,300 - 6 months of weekly updates: $1,900 - 12 months of weekly updates: $2,600 - Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (2 now), at most $750; people verified later in the term at no charge - Pricing: https://www.erudio.com/pricing - Buy now (card, through Stripe): https://www.erudio.com/reports/act-1-nct00646854 - Agents: POST https://www.erudio.com/api/orders with {"report": "act-1-nct00646854", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": ""}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again - Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=act-1-00646854 ## Cite Erudio Health. ACT-1 (NCT00646854): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/act-1-nct00646854 ## Machine access - JSON: https://www.erudio.com/reports/act-1-nct00646854.json - Markdown: https://www.erudio.com/reports/act-1-nct00646854.md - MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "act-1-00646854"}`